IJFANS International Journal of Food and Nutritional Sciences
-
“Geographical Analysis of Agricultural Productivity and Land Use Efficiency in Tribal Areas of Nashik District of Maharashtra”
Volume 13 | Issue 2
-
EXPLORING THE RELATIONSHIP OF SEXUAL PREFERENCE WITH RESPECT TO PERSONALITY AMONG YOUNG ADULTS (18-26 YEARS)
Volume 13 | Issue 2
-
Biochemical characterization of different tea
Volume 13 | Issue 2
-
INTRUSION DETECTION SYSTEM USING MACHINE LEARNING
Volume 13 | Issue 2
-
Machine Learning Insights into Non-Alcoholic Fatty Liver Disease Prediction
Volume 13 | Issue 2
A Recent Update of Ixekizumab in Moderate to Severe Plaque Psoriasis
Main Article Content
Abstract
Psoriasis is a chronic skin disease affecting millions of people globally. The most common type of psoriasis is plaque psoriasis. Currently FDA-approved Ixekizumab for the treatment of moderate to severe plaque psoriasis in adults. Ixekizumab is monoclonal antibody with high affinity. It selectively targets IL-17A and is indicated for the treatment. It is phase III of clinical trials and three phases of phase III clinical trials were conducted for safety and efficacy, namely UNCOVER I, UNCOVER II and UNCOVER III. Previously conducted various study was reviewed and analyzed in this study. Ixekizumab has proved to be safe and efficacious in the treatment of moderate to severe plaque psoriasis.
